Patents by Inventor Shigeki Seto
Shigeki Seto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230082516Abstract: [Problem] To provide a compound having a 15-PGDH inhibitory effect. [Solution] A compound represented by general formula (1) or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: January 7, 2020Publication date: March 16, 2023Applicant: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Shigeki SETO, Hitomi YAMADA, Yoshifumi SAITO, Haruaki KURASAKI
-
Publication number: 20170008888Abstract: Provided herein are compounds of formula I and compositions containing the compounds. The compounds and compositions are useful in the methods of inhibiting the action of ERK5, a BET family protein or both. In certain embodiments, the compounds and compositions are useful in the prevention, amelioration or treatment of a ERK5-mediated disease, a BET protein-mediated disease or both.Type: ApplicationFiled: February 26, 2015Publication date: January 12, 2017Inventors: Yi Hu, Emme C. K. Lin, Bei Li, Shyama Sidique, Jonathan S. Rosenblum, Oana M. Cociorva, Kevin R. Shreder, Shigeki Seto
-
Patent number: 8901112Abstract: Provided herein are spirocyclic aminoquinolones of formula I and compositions containing the compounds. The compounds and compositions provided herein are useful in the prevention, amelioration or treatment of GSK-3 inhibitors mediated diseases.Type: GrantFiled: May 24, 2013Date of Patent: December 2, 2014Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Oana Cociorva, Yasumichi Fukuda, Yasushi Kohno, Bei Li, Kyoko Okada, Ayako Nakamura, Masahiro Nomura, Shigeki Seto, Anna Katrin Szardenings, Kazuhiro Yumoto
-
Patent number: 8815903Abstract: The present invention provides a compound represented by the general formula (I) of the present invention, which has EP1 receptor antagonism: wherein A represents a benzene ring, a pyridine ring, or the like; Y1 represents a C1-6 alkylene group or the like; Y2 represents a single bond or the like; Z represents —C(?O)—NHSO2R6, an acidic 5-membered hetero ring group, or the like; R1 represents a hydrogen atom or the like; R2 represents a phenyl group, a 5-membered aromatic heterocyclic group, or the like; R3 represents a halogen atom, a C1-6 alkoxy group, or the like; R4 represents a hydrogen atom, a halogen atom, or the like; R5 represents a hydrogen atom or the like; and R6 represents a C1-6 alkyl group or the like], or a pharmaceutically acceptable salt thereof. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.Type: GrantFiled: January 24, 2012Date of Patent: August 26, 2014Assignees: Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd.Inventors: Kazuya Tatani, Atsushi Kondo, Tatsuhiro Kondo, Naohiro Kawamura, Shigeki Seto, Yasushi Kohno
-
Patent number: 8796247Abstract: The present invention provides a compound represented by the general formula (I) of the present invention, which has EP1 receptor antagonism: wherein A represents a pyridine ring, a furan ring, or the like; Y1 represents a C1-6 alkylene group; Y2 represents a single bond or the like; R1 represents —C(?O)—NH—SO2R6, an acidic 5-membered hetero ring group, or the like; R2 represents an optionally substituted phenyl group, an optionally substituted 5-membered aromatic heterocyclic group, or the like; R3 represents a halogen atom, a C1-6 alkoxy group, or the like; R4 represents a hydrogen atom, a halogen atom, or the like; R5 represents a hydrogen atom or the like; and R6 represents a C1-6 alkyl group or the like], and a pharmaceutically acceptable salt thereof. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.Type: GrantFiled: January 24, 2012Date of Patent: August 5, 2014Assignees: Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd.Inventors: Kazuya Tatani, Atsushi Kondo, Tatsuhiro Kondo, Naohiro Kawamura, Shigeki Seto, Yasushi Kohno
-
Publication number: 20140018335Abstract: The present invention provides a compound represented by the general formula (I) of the present invention, which has EP1 receptor antagonism: wherein A represents a pyridine ring, a furan ring, or the like; Y1 represents a C1-6 alkylene group; Y2 represents a single bond or the like; R1 represents —C(?O)—NH—SO2R6, an acidic 5-membered hetero ring group, or the like; R2 represents an optionally substituted phenyl group, an optionally substituted 5-membered aromatic heterocyclic group, or the like; R3 represents a halogen atom, a C1-6 alkoxy group, or the like; R4 represents a hydrogen atom, a halogen atom, or the like; R5 represents a hydrogen atom or the like; and R6 represents a C1-6 alkyl group or the like], and a pharmaceutically acceptable salt thereof. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.Type: ApplicationFiled: January 24, 2012Publication date: January 16, 2014Applicant: Kissei Pharmaceutical Co., Ltd.Inventors: Kazuya Tatani, Atsushi Kondo, Tatsuhiro Kondo, Naohiro Kawamura, Shigeki Seto, Yasushi Kohno
-
Publication number: 20140005184Abstract: Provided herein are spirocyclic aminoquinolones of formula I and compositions containing the compounds. The compounds and compositions provided herein are useful in the prevention, amelioration or treatment of GSK-3 inhibitors mediated diseases.Type: ApplicationFiled: May 24, 2013Publication date: January 2, 2014Applicant: KYORIN PHARMACEUTICALS CO., LTD.Inventors: Oana COCIORVA, Yasumichi FUKUDA, Yasushi KOHNO, Bei LI, Kyoko OKADA, Ayako NAKAMURA, Masahiro NOMURA, Shigeki SETO, Anna Katrin SZARDENINGS, Kazuhiro YUMOTO
-
Publication number: 20130331378Abstract: A pyrazolopyridine derivative represented by the following formula (I) or a pharmacologically acceptable salt thereof exhibits a strong EP1 receptor antagonistic effect. Thus, the derivative or the pharmacologically acceptable salt is useful as a therapeutic agent for lower urinary tract symptoms (LUTS), particularly, overactive bladder syndrome (OABs), or a prophylactic agent therefor and furthermore, is also useful in the treatment, prevention, or suppression of various pathological conditions in which the EP1 receptor is involved, such as inflammatory disease, pain disease, osteoporosis, and cancer. [A is a benzene ring or the like, Y1 is C1-6 alkylene, R1 is —C(?O)—OZ1 or the like, Z1 is H or the like, R2 is a branched C3-6 alkyl group or the like, R3 is H or the like, R4 is a hydrogen atom or the like, and R5 is a hydrogen atom or the like].Type: ApplicationFiled: January 25, 2012Publication date: December 12, 2013Applicants: KISSEI PHARMACEUTICAL CO., LTD., KYORIN PHARMACEUTICAL CO., LTD.Inventors: Shigeki Seto, Kentaro Umei, Yosuke Nishigaya, Asao Tanioka, Tatsuhiro Kondo, Atsushi Kondo, Kazuya Tatani, Naohiro Kawamura
-
Publication number: 20130317065Abstract: The present invention provides a compound represented by the general formula (I) of the present invention, which has EP1 receptor antagonism: wherein A represents a benzene ring, a pyridine ring, or the like; Y1 represents a C1-6 alkylene group or the like; Y2 represents a single bond or the like; Z represents —C(?O)—NHSO2R6, an acidic 5-membered hetero ring group, or the like; R1 represents a hydrogen atom or the like; R2 represents a phenyl group, a 5-membered aromatic heterocyclic group, or the like; R3 represents a halogen atom, a C1-6 alkoxy group, or the like; R4 represents a hydrogen atom, a halogen atom, or the like; R5 represents a hydrogen atom or the like; and R6 represents a C1-6 alkyl group or the like], or a pharmaceutically acceptable salt thereof. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.Type: ApplicationFiled: January 24, 2012Publication date: November 28, 2013Inventors: Kazuya Tatani, Atsushi Kondo, Tatsuhiro Kondo, Naohiro Kawamura, Shigeki Seto, Yasushi Kohno
-
Patent number: 8476261Abstract: Provided herein are spirocyclic aminoquinolones of formula I and compositions containing the compounds. The compounds and compositions provided herein are useful in the prevention, amelioration or treatment of GSK-3 inhibitors mediated diseases. In Formula (I): X1 is O or NR8; A is bond or substituted or unsubstituted C1-C2 alkylene, wherein the substituents when present are selected from one to four Q2 groups; where Q2 is alkyl or haloalkyl; p is 0 or 1; and q is an integer of 0 to 2.Type: GrantFiled: September 12, 2008Date of Patent: July 2, 2013Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Oana Cociorva, Yasumichi Fukuda, Yasushi Kohno, Bei Li, Kyoko Okada, Ayako Nakamura, Masahiro Nomura, Shigeki Seto, Anna Katrin Szardenings, Kazuhiro Yumoto
-
Patent number: 8063221Abstract: Provided herein are aminoquinolones and pharmaceutically acceptable derivatives thereof. In certain embodiments, provided herein are compounds, compositions and methods for treating, preventing or ameliorating GSK-3 mediated diseases.Type: GrantFiled: March 13, 2007Date of Patent: November 22, 2011Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Oana Cociorva, Bei Li, Anna Katrin Szardenings, Yasumichi Fukuda, Masahiro Nomura, Shigeki Seto, Kazuhiro Yumoto, Kyoko Okada, Ayako Nakamura
-
Publication number: 20110034436Abstract: Provided herein are spirocyclic aminoquinolones of formula I and compositions containing the compounds. The compounds and compositions provided herein are useful in the prevention, amelioration or treatment of GSK-3 inhibitors mediated diseases. In Formula (I): X1 is O or NR8; A is bond or substituted or unsubstituted C1-C2 alkylene, wherein the substituents when present are selected from one to four Q2 groups; where Q2 is alkyl or haloalkyl; p is 0 or 1; and q is an integer of 0 to 2.Type: ApplicationFiled: September 12, 2008Publication date: February 10, 2011Inventors: Oana Cociorva, Yasumichi Fukuda, Yasushi Kohno, Bei Li, Kyoko Okada, Ayako Nakamura, Masahiro Nomura, Shigeki Seto, Anna Katrin Szardenings, Yumoto Kazuhiro
-
Publication number: 20070254866Abstract: Provided herein are aminoquinolones and pharmaceutically acceptable derivatives thereof. In certain embodiments, provided herein are compounds, compositions and methods for treating, preventing or ameliorating GSK-3 mediated diseases.Type: ApplicationFiled: March 13, 2007Publication date: November 1, 2007Inventors: Oana Cociorva, Bei Li, Katrin Szardenings, Yasumichi Fukuda, Masahiro Nomura, Shigeki Seto, Kazuhiro Yumoto, Kyoko Okada, Ayako Nakamura
-
Patent number: 7064119Abstract: A novel fused bicyclic pyrimidine derivative or a salt thereof that acts as a tachykinin receptor antagonist and, in particular, as an NK1 receptor antagonist is represented by the following general formula (1): wherein the rings A and B are each a benzene ring having 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring); the ring C is a nitrogen-containing ring; R is a hydrogen atom, a C1 to C6 alkyl group, a C1 to C6 alkylcarbonyl group, or a C1 to C6 alkylsulfonyl group; m is 1 or 2; and n is 2 or 3.Type: GrantFiled: March 24, 2003Date of Patent: June 20, 2006Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Shigeki Seto, Asao Tanioka, Makoto Ikeda, Shigeru Izawa
-
Patent number: 7030107Abstract: A novel fused bicyclic pyridine derivative or a salt thereof that acts as a tachykinin receptor antagonist, in particular as an NK1 receptor antagonist, is represented by the following general formula (1): wherein the rings A and B are each a benzene ring which may have 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring); the ring C is a nitrogen-containing ring having a hydrogen atom substituted with a nitrogen atom; R1 and R2 are each independently a hydrogen atom, a C1 to C6 alkyl group, a C1 to C6 alkylsulfonyl group, a C1 to C6 alkylcarbonyl group, or a C1 to C6 alkoxycarbonyl group, or R1 and R2 are bound to one another to form the ring D; m is 1 or 2; n is 2 or 3; and q is an integer from 1 to 4.Type: GrantFiled: December 6, 2002Date of Patent: April 18, 2006Assignee: Kyorin Pharmaceutical.Co., Ltd.Inventors: Shigeki Seto, Asao Tanioka, Makoto Ikeda, Shigeru Izawa
-
Patent number: 7026309Abstract: A fused bicyclic pyridine derivative represented by the following general formula (1), or a salt thereof: wherein the rings A and B are each a benzene ring, which may have 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring) that are each independently selected from the group consisting of a halogen atom, a substituted or unsubstituted C1 to C6 alkyl group, and a substituted or unsubstituted C1 to C6 alkoxyl group; R is a C1 to C6 alkylsulfonyl group, a C1 to C6 alkylcarbonyl group, a C1 to C6 alkoxycarbonyl group, or a formyl group; m is 1 or 2; n is 2 or 3; and q is 1 or 2.Type: GrantFiled: March 24, 2003Date of Patent: April 11, 2006Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Shigeki Seto, Asao Tanioka, Makoto Ikeda, Shigeru Izawa
-
Patent number: 6995153Abstract: A novel fused bicyclic pyrimidine derivative or a salt thereof that acts as a tachykinin receptor antagonist and, in particular, as an NK1 receptor antagonist is represented by the following general formula (1): wherein the rings A and B are each a benzene ring having 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring); the ring C is a nitrogen-containing ring; m is 1 or 2; and n is 2 or 3.Type: GrantFiled: January 15, 2003Date of Patent: February 7, 2006Assignee: Kyorin Pharmaceutical. Co., Ltd.Inventors: Shigeki Seto, Asao Tanioka, Makoto Ikeda, Shigeru Izawa
-
Publication number: 20050159409Abstract: A novel fused bicyclic pyrimidine derivative or a salt thereof that acts as a tachykinin receptor antagonist and, in particular, as an NK1 receptor antagonist is represented by the following general formula (1): wherein the rings A and B are each a benzene ring having 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring); the ring C is a nitrogen-containing ring; R is a hydrogen atom, a C1 to C6 alkyl group, a C1 to C6 alkylcarbonyl group, or a C1 to C6 alkylsulfonyl group; m is 1 or 2; and n is 2 or 3.Type: ApplicationFiled: March 24, 2003Publication date: July 21, 2005Inventors: Shigeki Seto, Asao Tanioka, Shigeru Izawa
-
Publication number: 20050107375Abstract: A novel fused bicyclic pyridine derivative or a salt thereof that acts as a tachykinin receptor antagonist, in particular as an NK1 receptor antagonist, is represented by the following general formula (1): wherein the rings A and B are each a benzene ring which may have 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring); the ring C is a nitrogen-containing ring having a hydrogen atom substituted with a nitrogen atom; R1 and R2 are each independently a hydrogen atom, a C1 to C6 alkyl group, a C1 to C6 alkylsulfonyl group, a C1 to C6 alkylcarbonyl group, or a C1 to C6 alkoxycarbonyl group, or R1 and R2 are bound to one another to form the ring D; m is 1 or 2; n is 2 or 3; and q is an integer from 1 to 4.Type: ApplicationFiled: December 6, 2002Publication date: May 19, 2005Inventors: Shigeki Seto, Asao Tanioka, Makoto Ikeda, Shigeru Izawa
-
Publication number: 20050101591Abstract: A fused bicyclic pyridine derivative represented by the following general formula (1), or a salt thereof: wherein the rings A and B are each a benzene ring, which may have 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring) that are each independently selected from the group consisting of a halogen atom, a substituted or unsubstituted C1 to C6 alkyl group, and a substituted or unsubstituted C1 to C6 alkoxyl group; R is a C1 to C6 alkylsulfonyl group, a C1 to C6 alkylcarbonyl group, a C1 to C6 alkoxycarbonyl group, or a formyl group; m is 1 or 2; n is 2 or 3; and q is 1 or 2.Type: ApplicationFiled: March 24, 2003Publication date: May 12, 2005Inventors: Shigeki Seto, Asao Tanioka, Makoto Ikeda, Shigeru Izawa